(Q33416494)

26 July 2017

0 references

Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation (English)

1 reference

25034748

acute respiratory distress syndrome

26 July 2017

main subject

1 reference

1 reference

1 reference

chronic idiopathic myelofibrosis

1 reference

Yan Beauverd

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25034748%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Kaveh Samii

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25034748%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

18 July 2014

1 reference

25034748

International Journal of Hematology

26 July 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25034748%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25034748%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25034748%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

498-501

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25034748%20AND%20SRC:MED&resulttype=core&format=json

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Somatic mutations of calreticulin in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Hematopoietic stem cell transplantation for myelofibrosis: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Allogeneic stem cell transplantation for myelofibrosis in 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

Ruxolitinib withdrawal syndrome leading to tumor lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1628-5

10.1007/S12185-014-1628-5

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25034748%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

12 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25034748%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

25034748

1 reference